BR112017027702A2 - anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) - Google Patents
anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)Info
- Publication number
- BR112017027702A2 BR112017027702A2 BR112017027702A BR112017027702A BR112017027702A2 BR 112017027702 A2 BR112017027702 A2 BR 112017027702A2 BR 112017027702 A BR112017027702 A BR 112017027702A BR 112017027702 A BR112017027702 A BR 112017027702A BR 112017027702 A2 BR112017027702 A2 BR 112017027702A2
- Authority
- BR
- Brazil
- Prior art keywords
- vegfr2
- antibodies
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187204P | 2015-06-30 | 2015-06-30 | |
| PCT/US2016/040183 WO2017004254A1 (en) | 2015-06-30 | 2016-06-29 | Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017027702A2 true BR112017027702A2 (pt) | 2018-08-28 |
Family
ID=57609558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017027702A BR112017027702A2 (pt) | 2015-06-30 | 2016-06-29 | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180193456A1 (https=) |
| EP (1) | EP3316908A4 (https=) |
| JP (1) | JP2018528759A (https=) |
| KR (1) | KR20180021136A (https=) |
| CN (1) | CN108025067A (https=) |
| AU (1) | AU2016288192A1 (https=) |
| BR (1) | BR112017027702A2 (https=) |
| CA (1) | CA2990450A1 (https=) |
| HK (1) | HK1254048A1 (https=) |
| RU (1) | RU2018103192A (https=) |
| TW (1) | TW201718641A (https=) |
| WO (1) | WO2017004254A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201736399A (zh) | 2015-12-31 | 2017-10-16 | 財團法人生物技術開發中心 | 抗vegfr抗體及其應用 |
| CN106674349B (zh) * | 2017-03-07 | 2018-03-13 | 北京东方百泰生物科技有限公司 | 一种改进的抗vegfr‑2单克隆抗体 |
| TWI665213B (zh) * | 2017-06-29 | 2019-07-11 | 財團法人生物技術開發中心 | 抗人類血管內皮生長因子受體之抗體及其應用 |
| JP7339325B2 (ja) * | 2018-03-20 | 2023-09-05 | ナショナル ヘルス リサーチ インスティテューツ | 単離抗体、医薬組成物、単離抗体結合体、ダイマー化阻害方法、シグナル伝達阻害方法、管新生阻害方法、治療方法、および断片検出方法 |
| WO2021013061A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 一种人源化抗vegfr2抗体及其应用 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN113480653B (zh) * | 2021-08-06 | 2022-05-06 | 朱有建 | 一种含有γδT细胞的药物组合物在治疗癌症中的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2183028A2 (en) * | 2007-07-25 | 2010-05-12 | AstraZeneca AB | Targeted binging agents directed to kdr and uses thereof - 035 |
| EP3103814A1 (en) * | 2007-11-26 | 2016-12-14 | Bayer Intellectual Property GmbH | Anti-mesothelin antibodies and uses therefor |
| US8128932B2 (en) * | 2009-08-17 | 2012-03-06 | Shanghai Aosaiersi Biotech Co., Ltd. | Anti-VEGFR monoclonal antibody, method of making and uses thereof |
| US9029510B2 (en) * | 2012-03-30 | 2015-05-12 | Sorrento Therapeutics, Inc. | Fully human antibodies that bind to VEGFR2 and methods of use thereof |
| PL3685855T3 (pl) * | 2012-10-05 | 2024-04-08 | Kadmon Corporation, Llc | Ludzkie przeciwciała anty-vegfr-2/kdr |
-
2016
- 2016-06-29 EP EP16818720.1A patent/EP3316908A4/en not_active Withdrawn
- 2016-06-29 WO PCT/US2016/040183 patent/WO2017004254A1/en not_active Ceased
- 2016-06-29 US US15/740,790 patent/US20180193456A1/en not_active Abandoned
- 2016-06-29 AU AU2016288192A patent/AU2016288192A1/en not_active Abandoned
- 2016-06-29 JP JP2017567294A patent/JP2018528759A/ja active Pending
- 2016-06-29 RU RU2018103192A patent/RU2018103192A/ru not_active Application Discontinuation
- 2016-06-29 CN CN201680049578.3A patent/CN108025067A/zh active Pending
- 2016-06-29 KR KR1020187002388A patent/KR20180021136A/ko not_active Withdrawn
- 2016-06-29 HK HK18113110.8A patent/HK1254048A1/zh unknown
- 2016-06-29 BR BR112017027702A patent/BR112017027702A2/pt not_active Application Discontinuation
- 2016-06-29 CA CA2990450A patent/CA2990450A1/en not_active Abandoned
- 2016-06-29 TW TW105120598A patent/TW201718641A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018103192A (ru) | 2019-07-30 |
| AU2016288192A1 (en) | 2018-01-04 |
| WO2017004254A1 (en) | 2017-01-05 |
| CN108025067A (zh) | 2018-05-11 |
| US20180193456A1 (en) | 2018-07-12 |
| CA2990450A1 (en) | 2017-01-05 |
| EP3316908A1 (en) | 2018-05-09 |
| HK1254048A1 (zh) | 2019-07-12 |
| JP2018528759A (ja) | 2018-10-04 |
| TW201718641A (zh) | 2017-06-01 |
| RU2018103192A3 (https=) | 2020-01-30 |
| KR20180021136A (ko) | 2018-02-28 |
| EP3316908A4 (en) | 2019-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017027702A2 (pt) | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) | |
| AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
| SA520411173B1 (ar) | Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137 | |
| MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| JOP20200078B1 (ar) | أجسام مضادة خاصة بـ cd47 وpd-l1 | |
| BR112019008634A2 (pt) | anticorpos anti-pd-l1 e variantes | |
| BR112019005129A2 (pt) | anticorpos anti-pd-1 | |
| JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
| UA122479C2 (uk) | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) | |
| EA201892774A1 (ru) | Антитела | |
| BR112018000769A2 (pt) | anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos | |
| JO3788B1 (ar) | تراكيب جسم مضاد لـ egfrviii وcd3 | |
| BR112022004047A2 (pt) | Proteínas de ligação multiespecíficas para o tratamento de câncer | |
| CL2013001468A1 (es) | Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre. | |
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| WO2016063026A3 (en) | Selective nav protein binders | |
| EA201690503A1 (ru) | Антитела | |
| WO2015184403A3 (en) | Anti-epidermal growth factor receptor (egfr) antibodies | |
| BR112016015678A2 (pt) | Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso | |
| BR112016017764A2 (pt) | anticorpo antidengue de amplo espectro | |
| EA202191658A1 (ru) | Антитела против фактора c2b комплемента человека и способы применения | |
| EA201790437A1 (ru) | Антигенсвязывающие белки, связывающиеся с cxcr3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |